Celcuity Inc. (CELC)
NASDAQ:CELC
Want to see CELC full AI Analyst Report?
CELC Stock Chart & Stats
$122.46
-$0.35(-2.63%)
At close: 4:00 PM EST
$122.46
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$11.28 - $151.02
Previous CloseN/A
Volume14.25K
Average Volume (3M)1.72M
Market Cap
$4.32B
Enterprise Value$6.53B
Total Cash (Recent Filing)$145.19M
Total Debt (Recent Filing)$195.58M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 06, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.89
Shares Outstanding48,766,290
10 Day Avg. Volume2,650,195
30 Day Avg. Volume1,720,501
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)52.11
Price to Sales (P/S)0.00
P/FCF Ratio-34.13
Enterprise Value/Market Cap1.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-75.06K
Enterprise Value/Ebitda-37.82
Forecast
1Y Price Target
$161.75Price Target Upside32.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.01
Revenue Forecast (FY)$53.82M
Bulls Say, Bears Say
Bulls Say
Phase III SuperiorityA Phase III win showing statistically significant and clinically meaningful PFS improvement versus an approved PAM inhibitor is a durable clinical differentiator. Superiority in a head-to-head trial strengthens label and formulary case, supports payer access and positions gedatolisib to become a new standard in second-line HR+/HER2- disease.
Commercial Org BuiltA fully staffed, experienced oncology commercial team materially reduces launch execution risk. Veteran sellers and payer/account outreach create durable distribution and reimbursement capabilities, accelerating uptake if approved and enabling faster realization of market opportunity versus peers who must build sales infrastructure post-approval.
Refinanced Debt / Extended RunwayRefinancing into long-dated convertible notes reduces near-term cash interest and extends maturities, improving funding flexibility through key regulatory and commercialization milestones. This structural capital change lowers refinancing risk and preserves cash for development and launch activities, supporting strategy execution over the medium term.
Bears Say
Heavy Cash BurnSustained, deep negative free cash flow and widening net losses mean the company must repeatedly access capital markets until revenue exists. Persistent burn increases dilution risk, restricts strategic optionality, and raises vulnerability to market or funding shocks absent a durable revenue stream or significantly reduced spending.
Elevated LeverageA sharp step-up in debt and collapsing equity increases solvency and covenant risk and reduces financial flexibility. Higher leverage constrains the company's ability to absorb setbacks, limits re-investment capacity, and raises the probability of dilutive financing or conversion when capital markets are required to fund operations.
Long Timelines & Regulatory NeedsMaterial regulatory and development timelines persist: even with near-term PDUFA outcomes, subcutaneous formulation and first-line expansion require additional studies and years of work. These structural delays prolong revenue onset, extend financing dependence, and raise execution risk around labeling, reimbursement and real-world adoption.
Celcuity News
CELC FAQ
What was Celcuity Inc.’s price range in the past 12 months?
Celcuity Inc. lowest stock price was $11.28 and its highest was $151.02 in the past 12 months.
What is Celcuity Inc.’s market cap?
Celcuity Inc.’s market cap is $4.32B.
When is Celcuity Inc.’s upcoming earnings report date?
Celcuity Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 51 days.
How were Celcuity Inc.’s earnings last quarter?
Celcuity Inc. released its earnings results on May 14, 2026. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.04 by $0.07.
Is Celcuity Inc. overvalued?
According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued.
Does Celcuity Inc. pay dividends?
Celcuity Inc. does not currently pay dividends.
What is Celcuity Inc.’s EPS estimate?
Celcuity Inc.’s EPS estimate is -1.11.
How many shares outstanding does Celcuity Inc. have?
Celcuity Inc. has 48,766,290 shares outstanding.
What happened to Celcuity Inc.’s price movement after its last earnings report?
Celcuity Inc. reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.04. Following the earnings report the stock price went up 2.197%.
Which hedge fund is a major shareholder of Celcuity Inc.?
Currently, no hedge funds are holding shares in CELC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$161.75 (32.08% Upside)
$161.75 (32.08% Upside)
Blogger Sentiment
Bullish
CELC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
628.65%
12-Months-Change
Fundamentals
Return on Equity
-244.61%
Trailing 12-Months
Asset Growth
88.04%
Trailing 12-Months
Company Description
Celcuity Inc.
Operating as a clinical-stage biotechnology company, Celcuity Inc. is dedicated to pioneering precision cancer treatments for patients across the United States. At the heart of their approach is the CELsignia diagnostic platform, which examines live tumor cells from patients. This innovative system aims to uncover the precise cellular dysfunction fueling an individual's cancer, thereby guiding the selection of the most appropriate targeted therapeutic intervention. Among its pipeline of drug candidates is Gedatolisib, an agent engineered to selectively inhibit class I PI3K isoforms and mammalian target of rapamycin (mTOR). This therapy is being developed specifically for advanced or metastatic breast cancer patients who are hormone receptor positive and HER2-negative. Celcuity is also advancing the CELsignia MP test, a qualitative lab-developed assay designed to quantify HER2, c-Met, and PI3K signaling activity within both breast and ovarian tumor cells. The company secured a licensing agreement with Pfizer, Inc. for the development and commercialization rights pertaining to Gedatolisib. Established in 2011, Celcuity Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
CELC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was clinically very positive: robust Phase III efficacy signals in both wild-type and mutant cohorts, expansion into first-line studies, promising prostate cancer combo data, IP and formulation work for a subcutaneous version, and a staffed commercial organization targeting a large (~$5B+) second-line market and potential peak revenues up to $2.5B. Offsetting these achievements are materially higher losses and cash burn (net loss up ≈43%, non-GAAP loss up ≈35%, operating cash use up ≈54%), a large increase in SG&A (≈176%), runway that extends through 2027 only with debt drawdowns, and regulatory/clinical timelines (notably first-line data by 2028–2030 and potential additional studies for subcutaneous formulation) that delay broader commercialization. On balance, strong clinical progress and commercial preparations outweigh the near-term financial and timing challenges, but the company will need to manage cash and regulatory requirements closely.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$161.75
▲(32.08% Upside)
Technical Analysis
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
24.35% Insiders
11.80% Mutual Funds
9.67% Other Institutional Investors
44.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---